NL-OMON21852招募中不适用
Zevalin (90Yttrium-ibritumomab tiuxetan)-BEAM and autologous stem cell transplantation or single dose 90Yttrium ibritumomab tiuxetan as consolidation of induction chemotherapy in patients with transformed non-Hodgkin’s lymphoma. A phase II clinical trial.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- VUmc
- 入组人数
- 58
研究概览
简要总结
none
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. First diagnosis of transformation of lymphoma;
- •2. Histologically confirmed CD20 positive transformed B cell NHL lymphoma, according to the WHO classification 2008, stage I-IV;
排除标准
- •1. Known hypersensitivity to murine antibodies or proteins;
- •2. Presence of any other active neoplasms or history of prior malignancy, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma during the past 5 years;
研究者
相似试验
已完成
2 期
Zevalin (90Yttrium-ibritumomab tiuxetan)-BEAM and autologous stem cell transplantation or single dose 90Yttrium ibritumomab tiuxetan as consolidation of induction chemotherapy in patients with transformed non-Hodgkin*s lymphoma. ;A phase II clinical trialtransformed lymphomatransformed non-Hodgkin's lymphoma10025320NL-OMON39525Vrije Universiteit Medisch Centrum58
进行中（未招募）
不适用
Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years. - NDEUCTR2008-003828-38-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
进行中（未招募）
不适用
90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) - ZENOEUCTR2007-004289-42-GRational and Kapodistrian University of Athens40
终止
1 期
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's MacroglobulinemiaLymphomaNCT00060294Jonsson Comprehensive Cancer Center
已完成
2 期
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)LymphomaLeukemiaNCT01490723M.D. Anderson Cancer Center20